Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Bone Loss Prevention in Breast Cancer
NCT00107263Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in osteoporosis (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Average intra-patient change in total lumbar spine (L1-L4) bone mineral density at 12 months. Started Jan 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00107263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107263.